Viking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws Focus
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Viking Therapeutics (VKTX) is drawing attention after presenting new VK2735 obesity data, leading to short-term stock momentum despite a negative one-year return. Simply Wall St's bullish analyst narrative suggests the stock is 77% undervalued with a fair value of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context